Impact of the Novel MRI Contrast Agent Gadopiclenol on Radiotherapy Decision Making in Patients With Brain Metastases
Gadopiclenol-enhanced MRI improved BM detection and characterization, with a direct impact on radiotherapy treatment decision between WBRT and SRS. Additionally, a more exact target delineation and planning could be performed with gadopiclenol. A prospective evaluation in a larger cohort of patients is required to confirm these findings.
Authors
- Frank A. Giordano (ORCID: https://orcid.org/0000-0001-5243-4781)
- Frederik Wenz
- Florian Stieler
- Martin Bendszus (ORCID: https://orcid.org/0000-0002-9094-6769)
- Leonard Christopher Schmeel (ORCID: https://orcid.org/0000-0002-3901-4122)
- Andreas Feißt (ORCID: https://orcid.org/0000-0002-5672-3297)
- Gustavo R. Sarria (ORCID: https://orcid.org/0000-0002-5929-7270)
- Arne Mathias Ruder
- Jens Fleckenstein
- Miriam Eckl (ORCID: https://orcid.org/0000-0002-8748-9704)
- Marco Essig (ORCID: https://orcid.org/0000-0002-7964-2297)
- David Koch (ORCID: https://orcid.org/0000-0002-7866-9543)
Institutions
- University of Mannheim (DE)
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
- Ferioli & Gianotti (Italy) (IT)
- University Medical Centre Mannheim (DE)
Publication Details
- Journal
- Investigative Radiology
- Published
- 2024-08-19
- DOI
- https://doi.org/10.1097/rli.0000000000001115
- Citations
- 10
- Primary Topic
- Brain Metastases and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 3.77